The US Food and Drug Administration (FDA) has approved Synchron‘s Investigational Device Exemption (IDE) application for its flagship product, the Stentrode motor neuroprosthesis, the company reports.

This early feasibility study (EFS) of the device will begin later in 2021 at Mount Sinai Hospital, New York, and will assess the safety and efficacy of the interface in patients with severe paralysis. Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.

The FDA granted Breakthrough Device designation to Synchron in August 2020, according to a news release.

“The approval of this IDE reflects years of safety testing performed in conjunction with FDA. We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted BCI for the treatment of paralysis. We are thrilled to finally be launching a US clinical trial this year.”

— Synchron CEO Thomas Oxley, MD, PhD

Solves Multiple Challenges

Synchron’s technology solves multiple challenges that have restricted the commercial translation of BCIs out of the experimental laboratory. Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long-term brain inflammation.

The Stentrode device is delivered into the brain via the blood vessels in a minimally invasive 2-hour procedure, similar to the insertion of stents in the heart. No robotic assistance is required for the procedure, which can be performed in widely available angiography suites. The implant is fully internalized with no wires coming out of the head or body.

Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. The system is designed to facilitate better communication and functional independence for patients by enabling daily tasks like texting, emailing, online commerce, and accessing telemedicine.

“Synchron’s north star is to achieve whole-brain data transfer,” Oxley continues. “The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”

COMMAND Trial Set to Begin

Synchron is collaborating with Carnegie Mellon University, the University of Pittsburgh Medical Center and Mount Sinai Health System, New York City, on the new study, the COMMAND trial. A total of six patients are planned for the trial, with enrollment beginning later this year.

Synchron continues to evaluate the device in the SWITCH clinical trial currently underway in Australia. Four patients have received the Stentrode implant and are utilizing this neuroprosthesis for data transfer from motor cortex to control digital devices. Data from the first two patients in this study, which were published in the Journal of NeuroInterventional Surgery (JNIS) in October 2020, demonstrated each patient was able to control their devices to text and type through direct thought.

Following implantation and a short period of machine learning-assisted training, they were able to use the system unsupervised in their homes to send text messages, do online shopping and manage their finances.

[Source(s): Synchron Inc, Business Wire]

Related Content:
FDA Names Synchron’s Stentrode Brain-Computer Interface a Breakthrough Device
ALS Patients Perform Tasks with Thoughts
Stentrode Brain-Computer Interface Implanted Successfully for the First Time